A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation

H. Zaghla, R. R. Selby, L. S. Chan, J. A. Kahn, J. A. Donovan, N. Jabbour, Y. Genyk, R. Mateo, S. Gagandeep, L. S. Sher, E. Ramicone, T. L. Fong*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


Background: Sirolimus is a potent immunosuppressive agent whose role in liver transplantation has not been well-described. Aim: To evaluate the efficacy and side-effects of sirolimus-based immunosuppression in liver transplant patients. Methods: Retrospective analysis of 185 patients who underwent orthotopic liver transplantation. Patients were divided into three groups: group SA, sirolimus alone (n = 28); group SC, sirolimus with calcineurin inhibitors (n =56) and group CNI, calcineurin inhibitors without sirolimus (n = 101). Results: One-year patient and graft survival rates were 86.5% and 82.1% in group SA, 94.6% and 92.9% in group SC, and 83.2% and 75.2% in group CNI (P = N.S.). The rates of acute cellular rejection at 12 months were comparable among the three groups. At the time of transplantation, serum creatinine levels were significantly higher in group SA, but mean creatinine among the three groups at 1 month was similar. More patients in group SA required dialysis before orthotopic liver transplantation (group SA, 25%; group SC, 9%; group CNI, 5%; P = 0.008), but at 1 year, post-orthotopic liver transplantation dialysis rates were similar. Conclusions: Sirolimus given alone or in conjunction with calcineurin inhibitors appears to be an effective primary immunosuppressant regimen for orthotopic liver transplantation patients. Further studies to evaluate the efficacy and side-effect profile of sirolimus in liver transplant patients are warranted.

Original languageEnglish
Pages (from-to)513-520
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Issue number4
StatePublished - Feb 2006
Externally publishedYes


Dive into the research topics of 'A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation'. Together they form a unique fingerprint.

Cite this